SNN
Smith & Nephew plc
NYSE · Healthcare · Medical - Devices · GB
$28.87
+0.63%Year over year
Reported trailing growth
- Revenue
- +11.4%
- EBITDA
- +20.4%
- EBIT
- +33.6%
- EPS
- +120.0%
- Free cash flow
- +411.5%
- Operating cash flow
- +124.4%
Forward estimates
Based on analyst estimates
- Revenue
- -85.1%
- EBITDA
- -74.8%
- EPS
- -73.1%
Three-year CAGR
- Revenue
- +5.7%
- EBITDA
- +5.1%
- EBIT
- +20.8%
- Net income
- +41.0%
- EPS
- +42.9%
- Free cash flow
- +97.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026